Verified Peptide ReviewLast reviewed: 18 April 2026
Compound Profile · Growth Hormone
Ipamorelin + Mod GRF 1-29
Ipamorelin combined with Mod GRF 1-29 (CJC-1295 without DAC) is a research-only pairing studied for enhanced growth hormone secretion via dual receptor activation.
LegalResearch onlyEvidenceStrongHuman useNot approved
8.8/ 10
Peptide Score
Evidence
Safety
Regulatory
Transparency
Quick verdict
Similar to CJC-1295 + Ipamorelin but with a shorter-acting GHRH component. Additive GH release observed in research.
Reality check
What this isn't
- Not approved for human use — research-only context
- No regulator has approved human use
- Side-effect profile not fully characterised
- Educational only — not medical advice
Full Ipamorelin + Mod GRF 1-29 review
Mod GRF 1-29 is CJC-1295 without the DAC moiety, providing shorter-acting GHRH stimulation.
Combined with ipamorelin, the pairing targets both GHRH-R and ghrelin/GHS-R for synergistic GH release.
Looking at alternatives?
Compounds with comparable research interest but different evidence, regulatory status, or risk profile.